NCT01943825View on ClinicalTrials.gov

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 5, 2013

Primary Completion Date

November 25, 2015

Study Completion Date

November 25, 2015

Conditions
DengueDengue FeverDengue Hemorrhagic Fever
Interventions
BIOLOGICAL

CYD Dengue Vaccine

0.5 mL, Subcutaneous

BIOLOGICAL

CYD Dengue Vaccine

0.5 mL, Subcutaneous

BIOLOGICAL

Japanese Encephalitis Vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Japanese Encephalitis Vaccine

0.5 mL, Intramuscular

Trial Locations (1)

13210

Syracuse

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01943825 - Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine | Biotech Hunter | Biotech Hunter